Use of repaglinide on a pregnant woman during embryogenesis - PubMed (original) (raw)

Case Reports

Use of repaglinide on a pregnant woman during embryogenesis

M A Mollar-Puchades et al. Diabetes Obes Metab. 2007 Jan.

Abstract

In the past few years, oral antihyperglycaemic agents have been considered as an alternative to insulin therapy in the treatment of gestational diabetes. There is still little information available on the safety of these drugs during pregnancy, but there have been several studies published regarding their use. Here we report on the case of a woman who took repaglinide up to the seventh week of pregnancy. Delivery occured with no complications and the newborn showed no malformations. Further studies are required to confirm the safety of repaglinide during pregnancy.

PubMed Disclaimer

Similar articles

• Oral hypoglycemic agents in pregnancy: their time has come.
  Langer O. Langer O. J Matern Fetal Neonatal Med. 2002 Dec;12(6):376-83. doi: 10.1080/jmf.12.6.376.383. J Matern Fetal Neonatal Med. 2002. PMID: 12683647 Review.
• Use of repaglinide during the first weeks of pregnancy in two type 2 diabetic women.
  Napoli A, Ciampa F, Colatrella A, Fallucca F. Napoli A, et al. Diabetes Care. 2006 Oct;29(10):2326-7. doi: 10.2337/dc06-1254. Diabetes Care. 2006. PMID: 17003317 No abstract available.
• A case of rosiglitazone exposure in the second trimester of pregnancy.
  Kalyoncu NI, Yaris F, Ulku C, Kadioglu M, Kesim M, Unsal M, Dikici M, Yaris E. Kalyoncu NI, et al. Reprod Toxicol. 2005 Mar-Apr;19(4):563-4. doi: 10.1016/j.reprotox.2004.11.003. Reprod Toxicol. 2005. PMID: 15749272
• [Management of type 2 diabetes mellitus during pregnancy].
  de Valk HW, Eekhoff EM. de Valk HW, et al. Ned Tijdschr Geneeskd. 2008 Jan 19;152(3):121-4. Ned Tijdschr Geneeskd. 2008. PMID: 18271455 Dutch.
• Treating the mother--protecting the unborn: the safety of hypoglycemic drugs in pregnancy.
  Klieger C, Pollex E, Koren G. Klieger C, et al. J Matern Fetal Neonatal Med. 2008 Mar;21(3):191-6. doi: 10.1080/14767050801929653. J Matern Fetal Neonatal Med. 2008. PMID: 18297574 Review.

Cited by

• A comparison of the anti-diabetic potential of d-ribose-l-cysteine with insulin, and oral hypoglycaemic agents on pregnant rats.
  Osinubi AAA, Medubi LJ, Akang EN, Sodiq LK, Samuel TA, Kusemiju T, Osolu J, Madu D, Fasanmade O. Osinubi AAA, et al. Toxicol Rep. 2018 Aug 9;5:832-838. doi: 10.1016/j.toxrep.2018.08.003. eCollection 2018. Toxicol Rep. 2018. PMID: 30140615 Free PMC article.
• Safety considerations with pharmacological treatment of gestational diabetes mellitus.
  Simmons D. Simmons D. Drug Saf. 2015 Jan;38(1):65-78. doi: 10.1007/s40264-014-0253-9. Drug Saf. 2015. PMID: 25542297 Review.
• Review of metformin and glyburide in the management of gestational diabetes.
  Carroll DG, Kelley KW. Carroll DG, et al. Pharm Pract (Granada). 2014 Oct;12(4):528. doi: 10.4321/s1886-36552014000400001. Epub 2014 Mar 15. Pharm Pract (Granada). 2014. PMID: 25580176 Free PMC article.
• Pharmacological Management of Gestational Diabetes Mellitus.
  Mukerji G, Feig DS. Mukerji G, et al. Drugs. 2017 Oct;77(16):1723-1732. doi: 10.1007/s40265-017-0807-0. Drugs. 2017. PMID: 28864965 Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wiley

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal